Posted by Michael Wonder on 23 Jun 2021
TGA approves first generic pomalidomide
23 June 2021 - The TGA has approved first generic version of Celgene's Pomalyst.
Pomalidomide JN, Pomalidomide Juno & Pomolide capsules, when used in combination with bortezomib and dexamethasone, are indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
Pomalidomide JN, Pomalidomide Juno & Pomalide capsules, when in combination with dexamethasone, are also indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
